littl
known
preval
mucos
antibodi
induc
infect
human
coronavirus
hcov
includ
recent
describ
strain
enzymelink
immunosorb
assay
measur
antihcov
igg
antibodi
serum
iga
antibodi
nasal
wash
specimen
collect
seven
us
site
adult
age
year
older
mean
age
year
chronic
obstruct
pulmonari
diseas
patient
least
one
chronic
diseas
patient
serum
antibodi
hcov
strain
antibodi
antibodi
antibodi
antibodi
antibodi
hcov
strain
nasal
wash
specimen
antibodi
antibodi
antibodi
antibodi
respect
p
proport
subject
iga
antibodi
nasal
wash
specimen
geometr
mean
iga
antibodi
titer
statist
higher
higher
proport
patient
heart
diseas
iga
antibodi
versu
p
correl
highest
serum
antibodi
titer
group
strain
r
p
group
ii
strain
r
p
statist
signific
patient
like
experienc
infect
one
hcov
strain
igg
antibodi
hcov
strain
serum
like
detect
iga
antibodi
hcov
strain
nasal
wash
specimen
coronavirus
compris
genu
famili
coronavirida
envelop
singlestrand
positivesens
rna
virus
four
human
coronaviru
hcov
strain
describ
associ
spectrum
diseas
mild
febril
upper
respiratori
tract
ill
sever
ill
includ
croup
bronchiol
pneumonia
wide
geograph
distribut
hcov
infect
contributor
sever
ill
requir
emerg
care
hospit
patient
chronic
medic
condit
earliestdescrib
hcov
strain
group
group
ii
coronavirus
respect
join
recent
describ
group
ii
strain
discov
search
pathogen
coronavirus
identif
coronaviru
caus
sever
acut
respiratori
syndrom
sar
may
infect
human
popul
long
time
sinc
diverg
phylogenet
year
ago
seropreval
would
like
high
result
crosssect
longitudin
seroepidemiolog
studi
found
larg
proport
children
healthi
adult
detect
serum
antibodi
four
hcov
strain
seroconvers
occur
often
childhood
seropreval
increas
age
reinfect
may
occur
inform
need
seropreval
virus
durabl
humor
immun
respons
correl
immun
mucos
antibodi
respons
hcov
infect
present
studi
question
whether
preval
antibodi
four
hcov
strain
would
differ
nasal
secret
serum
older
adult
veteran
underli
chronic
obstruct
pulmonari
diseas
copd
particip
depart
veteran
affair
cooper
studi
conveni
sampl
patient
met
spirometr
criteria
copd
enrol
larger
influenza
viru
vaccin
efficaci
trial
patient
year
age
chosen
analysi
substudi
preval
antibodi
hcov
residu
serum
nasal
wash
specimen
collect
time
subject
avail
analysi
subject
enrol
seven
geograph
divers
studi
site
unit
state
locat
follow
state
alabama
florida
illinoi
massachusett
michigan
missouri
texa
pair
serum
nasal
wash
specimen
collect
week
follow
influenza
viru
vaccin
octob
februari
associ
acut
respiratori
ill
time
collect
patient
gave
written
inform
consent
respons
committe
human
experiment
approv
studi
antigen
prepar
elisa
hcov
antigen
use
antibodi
enzymelink
immunosorb
assay
elisa
produc
describ
previous
obtain
american
type
cultur
collect
atcc
manassa
va
grown
cell
monolay
atcc
respect
grown
cell
monolay
gift
lia
van
der
hoek
univers
amsterdam
amsterdam
netherland
virusinfect
cell
frozen
thaw
three
time
supernat
fluid
clear
cell
debri
centrifug
viru
concentr
overnight
centrifug
viru
pellet
resuspend
phosphatebuff
salin
pb
concentr
viru
inactiv
psoralen
compound
sigma
st
loui
mo
follow
irradi
longwavelength
uv
light
describ
previous
mock
antigen
prepar
way
uninfect
cell
tag
recombin
n
protein
use
antigen
elisa
detect
antibodi
express
vector
novagen
inc
new
canaan
ct
encod
n
protein
clone
ecori
noti
site
frame
downstream
seri
sixhistidin
residu
describ
previous
gift
k
yuen
univers
hong
kong
hong
kong
recombin
n
protein
express
transform
singl
compet
cell
novagen
inc
plasmid
purifi
use
ni
load
hitrap
chelat
system
amersham
bioscienc
piscataway
nj
accord
manufactur
instruct
describ
previous
brief
transform
cell
disrupt
protein
sampl
prepar
isol
inclus
bodi
via
sonic
wash
protein
sampl
load
onto
hitrap
chelat
hp
column
prepack
precharg
highperform
ni
sepharos
protein
purifi
refold
serial
buffer
wash
column
liquid
chromatographi
fast
protein
liquid
chromatographi
fplc
system
pharmacia
lbk
biotechnolog
piscataway
nj
elut
protein
collect
fraction
fraction
analyz
presenc
protein
sdspage
protein
concentr
determin
biorad
protein
assay
biorad
laboratori
hercul
ca
adjust
gml
elisa
mock
antigen
produc
plasmid
dna
vector
without
n
protein
gene
sequenc
procedur
viral
antigen
respect
control
use
coat
flatbottom
maxisorp
immunopl
nalgenunc
intern
rochest
ny
measur
serum
igg
antibodi
sequenc
reagent
consist
serum
seri
eight
dilut
start
dilut
gener
broad
doserespons
curv
mous
antihuman
igg
fc
specif
conjug
horseradish
peroxidas
accur
chemic
scientif
westburi
ny
ophenylenediamin
substrat
kpl
gaithersburg
md
optic
densiti
od
measur
nm
use
tecan
research
triangl
park
nc
spectrophotomet
antihcov
antibodi
titer
elisa
calcul
referencelin
leastsquaresfit
method
cutoff
od
set
viral
antigen
level
least
twice
background
od
respect
mock
antigen
correspond
linear
rang
od
versu
reciprocaldilut
curv
measur
iga
antibodi
nasal
wash
specimen
nasal
wash
specimen
first
sonic
concentr
use
centrifug
filter
devic
centriprep
millipor
corp
ireland
accord
manufactur
instruct
concentr
nasal
wash
specimen
test
elisa
use
sera
except
nasal
wash
specimen
dilut
seri
six
dilut
start
dilut
goat
antihuman
iga
conjug
horseradish
peroxidas
mp
biomedicalscappel
solon
oh
employ
endpoint
antihcov
antibodi
titer
final
dilut
nasal
wash
specimen
od
antigenco
well
greater
least
twice
respect
control
describ
previous
total
iga
antibodi
concentr
nasal
wash
specimen
determin
previous
elisa
briefli
sequenc
reagent
begin
solid
phase
goat
antihuman
iga
icncappel
pharmaceut
inc
aurora
oh
nasal
wash
specimen
goat
antihuman
iga
specif
conjug
horseradish
peroxidas
ophenylenediamin
substrat
standard
curv
known
secretori
iga
concentr
determin
use
serial
dilut
human
secretori
iga
icn
biomed
inc
costa
mesa
ca
instead
nasal
wash
specimen
elisa
repeat
measur
total
iga
concentr
studi
find
decay
total
iga
concentr
specimen
store
year
initi
collect
antihcov
iga
antibodi
titer
nasal
wash
specimen
mathemat
adjust
arbitrari
total
iga
antibodi
concentr
mgliter
use
measur
total
iga
antibodi
concentr
specimen
statist
method
demograph
antibodi
data
analyz
use
descript
statist
reciproc
antibodi
titer
logarithm
transform
geometr
mean
titer
gmt
compar
use
wilcoxon
signedrank
test
mcnemar
test
use
compar
pairwis
proport
subject
detect
antihcov
antibodi
nonpair
data
compar
use
test
fisher
exact
test
wilcoxon
rank
sum
test
logarithm
transform
serum
igg
antibodi
titer
hcov
strain
assess
linear
regress
pearson
correl
perform
patient
studi
male
white
tabl
spirometr
confirm
obstruct
pulmonari
diseas
one
addit
underli
ill
year
age
older
tabl
least
patient
serum
igg
antibodi
serum
igg
antibodi
tabl
proport
patient
detect
igg
antibodi
greater
proport
igg
antibodi
p
p
p
respect
compar
serum
igg
antibodi
smaller
proport
patient
iga
antibodi
hcov
strain
nasal
wash
specimen
posit
posit
posit
posit
p
tabl
proport
patient
iga
antibodi
significantli
greater
iga
antibodi
p
p
respect
p
p
respect
tabl
antihcov
iga
antibodi
gmt
nasal
wash
specimen
detect
antibodi
within
dilut
rang
four
viral
strain
compar
tabl
gmt
higher
rang
individu
iga
antibodi
titer
includ
higher
valu
p
p
respect
p
serum
igg
antibodi
gmt
less
p
serum
igg
gmt
greater
p
serum
igg
antibodi
gmt
higher
rang
individu
igg
antibodi
titer
extend
higher
higher
tabl
sera
igg
antibodi
titer
spirometr
criteria
copd
fev
less
predict
valu
fev
fvc
ratio
less
describ
previous
fev
forc
expiratori
volum
fvc
forc
vital
capac
greater
highest
titer
sera
igg
antibodi
titer
greater
highest
titer
nasal
wash
specimen
iga
antibodi
one
hcov
strain
antibodi
anoth
viral
strain
tabl
five
nasal
wash
specimen
titer
iga
antibodi
exceed
highest
titer
specimen
none
five
specimen
detect
antibodi
similarli
seven
nasal
wash
specimen
iga
antibodi
titer
exceed
highest
titer
specimen
one
seven
specimen
antibodi
henc
crossreact
iga
antibodi
one
viral
strain
might
expect
hightit
specimen
often
present
strain
hcov
group
sinc
sera
igg
antibodi
four
hcov
strain
assess
correl
serum
igg
antibodi
titer
hcov
strain
character
possibl
antigen
relationship
hcov
strain
group
base
seroreact
highest
level
correl
strain
within
hcov
group
fig
group
ii
fig
comparison
serum
igg
antibodi
titer
hcov
strain
group
lower
correl
coeffici
either
statist
signific
weaker
signific
level
fig
f
observ
withingroup
comparison
fig
b
thu
data
also
consist
patient
experienc
infect
group
group
ii
hcov
strain
past
serum
igg
nasal
wash
specimen
iga
antibodi
gmt
hcov
strain
significantli
differ
current
smoker
compar
nonsmok
patient
histori
heart
diseas
compar
without
histori
heart
diseas
data
shown
proport
patient
nasal
wash
specimen
iga
antibodi
hcov
strain
current
smoker
compar
nonsmok
differ
significantli
data
shown
proport
iga
antibodi
nasal
wash
specimen
patient
histori
heart
diseas
higher
patient
without
heart
diseas
versu
p
proport
iga
antibodi
three
hcov
strain
nasal
wash
specimen
patient
without
heart
diseas
differ
data
shown
serum
igg
antibodi
four
hcov
strain
present
studi
subject
iga
antibodi
four
hcov
strain
detect
less
frequent
nasal
wash
specimen
gmt
geometr
mean
titer
calcul
inclus
specimen
sera
without
detect
antibodi
titer
hcov
arbitrarili
assign
titer
nasal
wash
nw
specimen
without
detect
antibodi
titer
hcov
arbitrarili
assign
titer
b
four
specimen
deplet
prior
finish
test
viral
antigen
c
signific
nonagr
antibodi
pair
p
p
p
respect
mcnemar
test
proport
serum
igg
antibodi
differ
proport
iga
antibodi
nasal
wash
specimen
hcov
strain
respect
p
gmt
greater
gmt
p
wilcoxon
signedrank
test
gmt
less
gmt
p
wilcoxon
signedrank
test
e
gmt
greater
gmt
p
wilcoxon
signedrank
test
f
signific
nonagr
antibodi
pair
antibodi
pair
p
p
respect
mcnemar
test
g
signific
nonagr
antibodi
pair
antibodi
pair
p
p
respect
mcnemar
test
h
gmt
less
gmt
p
p
respect
wilcoxon
signedrank
test
gmt
less
gmt
p
wilcoxon
signedrank
test
subject
patient
repres
broad
geograph
distribut
midwestern
southern
northeastern
region
unit
state
wide
rang
igg
iga
antibodi
titer
hcov
observ
level
mean
igg
antibodi
higher
level
mean
igg
antibodi
respect
nasal
wash
specimen
iga
antibodi
two
group
ii
hcov
strain
frequent
detect
antibodi
two
group
strain
mean
antibodi
titer
higher
group
ii
strain
well
sinc
mean
antibodi
titer
hcov
strain
serum
also
nasal
wash
specimen
within
rang
unclear
statist
differ
mean
titer
import
clinic
concomit
presenc
iga
antibodi
one
hcov
strain
observ
nasal
wash
specimen
univers
case
serum
igg
antibodi
hcov
find
may
reflect
previou
infect
patient
one
viral
strain
antibodi
crossreact
strain
due
hcov
groupspecif
rather
strainspecif
antigen
better
induct
mucos
iga
antibodi
certain
hcov
strain
shorter
period
detect
infect
secret
serum
better
preserv
antibodi
nasal
wash
specimen
antibodi
hcov
detect
antihcov
antibodi
despit
similar
storag
condit
howev
amount
total
iga
specimen
declin
storag
strainspecif
iga
antibodi
decay
storag
either
correl
serum
igg
antibodi
titer
within
across
hcov
group
show
strike
associ
level
antibodi
hcov
strain
within
group
across
group
may
reflect
antigen
crossreact
within
hcov
group
less
group
also
crossreact
iga
antibodi
hcov
strain
hcov
group
gener
observ
hightit
nasal
wash
specimen
level
serum
antibodi
studi
term
gmt
frequenc
detect
similar
data
report
previous
schmidt
et
al
describ
repeat
signific
increas
antibodi
longitudin
time
suggest
reinfect
occur
viru
strain
preval
serum
antibodi
studi
higher
report
previous
hruskova
et
al
czechoslovakia
higher
preval
serum
antibodi
children
adolesc
unit
state
report
previous
shao
et
al
similar
report
health
care
worker
franc
children
netherland
age
year
serum
antibodi
serum
sampl
collect
crosssect
respect
sever
et
al
previous
report
seropreval
rate
among
larg
adult
popul
maryland
seropreval
rate
lower
report
present
studi
seroepidemiolog
studi
famili
includ
children
young
adult
one
commun
high
preval
antibodi
report
frequent
reinfect
occur
despit
preexist
serum
antibodi
thu
evid
infect
virus
common
children
adult
occur
wide
geograph
distribut
frequent
time
identifi
differ
antibodi
titer
current
smoker
compar
nonsmok
unlik
report
sever
et
al
igg
antibodi
unclear
reason
patient
histori
heart
diseas
like
iga
antibodi
nasal
wash
specimen
studi
receptor
use
find
enter
target
cell
uniqu
among
group
ii
coronavirus
sar
coronaviru
receptor
angiotensinconvert
enzym
present
arteri
venou
endotheli
cell
arteri
smoothmuscl
cell
small
intestin
tracheobronchi
airway
epithelia
help
regul
reninangiotensinaldosteron
system
activ
heart
failur
inactiv
angiotensin
ii
play
role
protect
sever
acut
lung
injuri
among
human
coronavirus
particular
associ
croup
two
report
iga
antibodi
hcov
nasal
secret
could
found
literatur
callow
et
al
report
previous
iga
antibodi
detect
nasal
wash
specimen
experiment
infect
adult
viru
iga
antibodi
level
declin
followup
remain
higher
preinfect
level
week
later
anoth
previou
report
callow
suggest
antibodi
serum
nasal
wash
specimen
correl
protect
experiment
infect
diseas
iga
antibodi
nasal
wash
specimen
associ
reduc
durat
viral
shed
nasal
secret
henc
despit
nearunivers
presenc
serum
antibodi
hcov
strain
studi
lower
rate
detect
iga
antibodi
hcov
suggest
possibl
reason
suscept
reinfect
hcov
iga
antibodi
nasal
secret
inde
protect
summari
serum
igg
antibodi
four
hcov
strain
detect
patient
studi
appear
like
patient
may
experi
infect
one
strain
hcov
measur
iga
antibodi
hcov
serum
studi
sinc
interest
presenc
respiratori
secret
compart
iga
import
mediat
specif
immun
base
much
lower
frequenc
patient
hcovspecif
iga
antibodi
nasal
wash
specimen
igg
serum
older
adult
popul
one
might
hypothes
antibodi
hcov
nasal
secret
declin
titer
rapidli
infect
serum
antibodi
infect
induc
iga
antibodi
hcov
nasal
secret
high
titer
signific
proport
older
chronic
ill
patient
copd
whether
induct
virusspecif
mucos
iga
antibodi
hcov
infect
durabl
differ
older
chronic
ill
adult
younger
healthi
adult
children
requir
studi
delin
rel
import
iga
antibodi
nasal
secret
serum
igg
antibodi
immun
correl
protect
infect
hcov
role
antibodi
crossreact
among
hcov
strain
may
play
protect
pathogenesi
hcov
infect
would
assist
devis
approach
develop
vaccin
could
prevent
hcov
infect
